Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer

Abstract

A B S T R A C T PurposeDrugs are approved on the basis of randomized trials conducted in selected populations. However, once approved, these treatments are usually expanded to patients ineligible for the trial. Patients and MethodsWe used the SEER-Medicare database to identify subjects older than 65 years with metastatic breast, lung, and colon cancer, diagnosed between 2004 and 2007 and undergoing follow-up to 2009, who received bevacizumab. We defined a contraindication as having at least two billing claims before bevacizumab for thrombosis, cardiac disease, stroke, hemorrhage, hemoptysis, or GI perforation. We defined toxicity as first development of one of these conditions after therapy. ResultsAmong 16,085 metastatic patients identified, 3,039 (18.9%) received bevacizumab. Receipt of bevacizumab was associated with white race, later year of diagnosis, tumor type, and decreased comorbid conditions. Of patients who received bevacizumab, 1,082 (35.5%) had a contraindication. In multivariate analysis, receipt of bevacizumab with a contraindication was associated with black race (odds ratio [OR] ϭ 2.6; 95% CI, 1.4 to 4.9), increased age, comorbidity, later year of diagnosis, and lower socioeconomic status. Patients with lung (OR ϭ 1.7; 95% CI, 1.1 to 2.4) and colon cancer (OR ϭ 1.4; 95% CI, 1.1 to 1.9) were more likely to have a contraindication. In the group with no contraindication, 30% had a complication after bevacizumab; black patients were more likely to have a complication than were white patients (OR ϭ 1.9; 95% CI, 1.21 to 2.93). ConclusionOur study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed.

Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study

“…Another potential issue is that we included patients without recurrence for 36 months, and defined recurrence as receipt of a new chemotherapy regimen. Despite the fact that we used methods similar to those used in other studies to define recurrence, [40][41][42][43] we acknowledge that this approach may not capture patients who chose not to receive chemotherapy, as suggested by a recent paper. 44 We do not feel this would have had a large impact on our sample population, as we required that patients survive 3 years, which would have been less likely without chemotherapy.…”

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

“…Many studies have demonstrated that bevacizumab therapy is associated with an increased risk of gastrointestinal perforation, wound healing complications, hemorrhage, arterial thromboembolism, and reversible posterior leukoencephalopathy syndrome [11][12][13][14] . Therefore, patients with a history of bleeding, cerebrovascular accident, thrombotic disorders, and gastrointestinal perforation were excluded from participation in clinical trials [11] .…”

Advances in caring for the older cancer patient: a report from the 2015 conference of the International Society of Geriatric Oncology

“…The incidence and mortality of CRC rise steeply after the age of 55, and in both men and women are highest in the 75-84 age group 3 . For a less common cancer, that of oral cavity, the pattern is similar: in the elderly, the peak incidence for both sexes is double that in people aged 35-60 years 4 .…”